Varenicline

Varenicline Structure
CAS No.
249296-44-4
Chemical Name:
Varenicline
Synonyms
Chantix;Varenciline;10-tetrahydro-;7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline;(1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2,4(9),5,7,10-pentaene;CS-861;Hsdb 7591;Cp 526555;Vareniclene;VARENICLINE
CBNumber:
CB61011764
Molecular Formula:
C13H13N3
Molecular Weight:
211.26
MOL File:
249296-44-4.mol
Modify Date:
2024/7/2 8:55:12

Varenicline Properties

Melting point 138.5 °C
Boiling point 400.6±40.0 °C(Predicted)
Density 1.247±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility Soluble in DMSO
form Powder
pka 9.60±0.20(Predicted)
color Light yellow to yellow
BCS Class 1
Stability Hygroscopic

Varenicline Chemical Properties,Uses,Production

Description

Varenicline, a partial agonist of the a4b2 nicotinic receptor, is a first-in-class drug launched by Pfizer as an aid to smoking cessation treatment. Varenicline exhibits dual action by decreasing craving and withdrawal symptoms, and by decreasing the reinforcement associated with smoking. The addictive properties of nicotine are thought to be mediated in part through its action as an agonist at α4β2 neuronal nicotinic acetylcholine receptors (nAChRs). Activation of α4β2 receptors by nicotine increases the release of dopamine in the mesolimbic system, an effect that is shared by most drugs of abuse. As nicotine levels decrease, dopamine levels decline, which in turn stimulates the urge to smoke. Additionally, a reduced dopaminergic tone due to abstinence from smoking stimulates craving and the withdrawal syndrome. A partial agonist of α4β2 receptors such as varenicline is expected to elicit a moderate and sustained increase in dopamine levels to relieve craving and withdrawal symptoms. In addition, by competitively binding to a4b2 receptors and inhibiting nicotineinduced dopaminergic activation, a partial agonist could attenuate the pharmacologic reward associated with smoking.

Uses

Varenicline is a useful medication for smoking cessation.

Definition

ChEBI: An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.

Varenicline Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 175)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Aptus Therapeutics +91-9966349855 +91-9966349855 Telangana, India 19 58 Inquiry
BIOCHEMICAL & SYNTHETIC PRODUCTS PVT. LT., +91-91-8421973722 +91-9869455944 Telangana, India 31 58 Inquiry
SKVen Technologies Pvt.Ltd. +91-7032295152 +91-7032295152 Hyderabad, India 81 58 Inquiry
GLP Pharma Standards +91 9866074638 Hyderabad, India 1644 58 Inquiry
VGS SYNTHESIS PRIVATE LIMITED +91-9866975588 +91-9866975588 Hyderabad, India 1818 58 Inquiry
Svak Life Sciences +91-9963463333 +91-9705383777 Hyderabad, India 101 58 Inquiry
Opulant Pharmaceuticals Pvt Ltd +91-8105130349 +91-8105130349 Telangana, India 66 58 Inquiry
VIVAN Life Sciences Pvt Ltd +91-2225870080 +91-9987465183 Maharashtra, India 49 58 Inquiry
Riddhesh Pharmachem +91-9106014993 +91-9106014993 Gujarat, India 126 58 Inquiry
Venkatasai Life Sciences +91-9908134868 +91-8008303069 Hyderabad, India 186 58 Inquiry
3-h][3]benzazepine Varenicline Impurity VARENICLINE 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine Vareniclene Varenicline free base Cp 526555 Hsdb 7591 Unii-W6hs99o8zo 10-Methano-6H-pyrazino[2 6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine, 7,8,9,10-tetrahydro- CS-861 CP 526555;CHAMPIX;CHANTIX;CP526555;CP-526555 Varenicline base Varenicline (CP 526555) Varenicline 13C15N (1R,12S)-5,8,14-triazatetracyclo[10.3.1.0^{2,11}.0^{4,9}]hexadeca-2,4(9),5,7,10-pentaene 10-tetrahydro- 7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline Chantix Varenciline VERENICLINE Vancomycin Impurity 20 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine (Vareniclene) 249296-44-4 375815-87-8 API intermediates API